Janssen Vaccine and Prevention BV
Currently, I am Director Biomarkers heading a group of Biomarker Leads responsible for the immune parameters that are measured in clinical vaccine trials in addition to driving the discussions on go/no go criteria that support the next phase of clinical development for vaccine programs for HIV, RSV, Ebola, Zika, HPV, Flu and IPV. Most recently I have been closely involved in the immunological evaluation of our SARS-Cov-2 vaccine candidate and its progression through clinical studies.
After a PhD on CD27 in the specific immune response, a postdoc on cancer stem cells was completed. After working as a Scientist at Clinical Assays at Crucell where immunogenicity assays were developed and validated analysing the immune responses to the Adenovirus-based vaccines against diseases such as Malaria, HIV and TB, I transitioned into the role of Head Biomarkers. Here, I lead discussions on the immune parameters that should be measured in clinical vaccine trials in addition to driving the discussions on go/no go criteria that support the next phase of clinical development. I am responsible for translating preclinical data in expectations for clinical trial outcome focussing on adenoviral vector-based vaccine candidates